| KRYS Stock | | | USD 178.33 0.86 0.48% |
Krystal Biotech financial indicator trend analysis is infinitely more than just investigating Krystal Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Krystal Biotech is a good investment. Please check the relationship between Krystal Biotech Accounts Payable and its Total Current Assets accounts. Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in manufacturing.
For more information on how to buy Krystal Stock please use our
How to Invest in Krystal Biotech guide.
Accounts Payable vs Total Current Assets
Accounts Payable vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Krystal Biotech Accounts Payable account and
Total Current Assets. At this time, the significance of the direction appears to have strong relationship.
The correlation between Krystal Biotech's Accounts Payable and Total Current Assets is 0.79. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Krystal Biotech, assuming nothing else is changed. The correlation between historical values of Krystal Biotech's Accounts Payable and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Krystal Biotech are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Accounts Payable i.e., Krystal Biotech's Accounts Payable and Total Current Assets go up and down completely randomly.
Correlation Coefficient | 0.79 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Accounts Payable
An accounting item on the balance sheet that represents Krystal Biotech obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Krystal Biotech are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.
Most indicators from Krystal Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Krystal Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in manufacturing.
For more information on how to buy Krystal Stock please use our
How to Invest in Krystal Biotech guide.At this time, Krystal Biotech's
Selling General Administrative is comparatively stable compared to the past year.
Tax Provision is likely to gain to about 2.1
M in 2024, whereas
Sales General And Administrative To Revenue is likely to drop 3.24 in 2024.
Krystal Biotech fundamental ratios Correlations
Click cells to compare fundamentals
Krystal Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Krystal Biotech fundamental ratios Accounts
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to
measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to
predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.